Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data

J Am Acad Dermatol. 2017 Dec;77(6):1178-1180. doi: 10.1016/j.jaad.2017.06.162.

Authors

Alice B Gottlieb¹, Joseph F Merola², Rongdean Chen³, Eugenia Levi³, Kristina Callis Duffin⁴

Affiliations

¹ New York Medical College, Valhalla, New York. Electronic address: alicegottliebderm@gmail.com.
² Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Celgene Corporation, Summit, New Jersey.
⁴ University of Utah, Salt Lake City, Utah.

PMID: 29132853
DOI: 10.1016/j.jaad.2017.06.162

No abstract available

Publication types

Clinical Trial, Phase III
Letter
Randomized Controlled Trial

MeSH terms

Body Surface Area*
Humans
Psoriasis / diagnosis
Psoriasis / drug therapy*
Severity of Illness Index
Thalidomide / analogs & derivatives*
Thalidomide / therapeutic use
Treatment Outcome

Substances

Thalidomide
apremilast